Cell & Gene Therapy Investor Day

This event provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools.

The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology.

Matthew Durdy, Chief Business Officer at Cell and Gene Therapy Catapult will be attending the event. 

Discover who we are